背景:在多种非黑素瘤皮肤癌(NMSCs)中,使用PD-1或PD-L1抑制剂进行免疫治疗的报道越来越多。 目的:分析PD-1和PD-L1抑制剂治疗非黑素瘤皮肤癌的证据。 方法:截止到2018年10月28日,与PubMed,Cochrane图书馆EMBASE,Web of Science和CINAHL进行了初步文献检索,包括关于在人类中使用PD-1或PD-L1抑制剂的研究非黑色素瘤皮肤癌的受试者。两名审查员独立进行研究选择,数据提取和关键评估。 结果:该系统评价包含五十一条。在1期和2期临床试验的支持下,最有力的证据是治疗默克尔细胞癌和皮肤鳞状细胞癌。 PD-1 / PD-L1抑制剂对基底细胞癌,皮肤肉瘤,皮脂腺癌和恶性周围神经鞘瘤的治疗也显示出益处,但数据有限。 PD-1 / PD-L1抑制剂在皮肤淋巴瘤中似乎没有疗效。 局限性:需要进行更多的研究以确定PD-1和PD-L1抑制剂在NMSC中的疗效,肿瘤反应性和安全性。 结论:PD-1和PD-L1抑制剂在多种非黑素瘤皮肤癌中均具有治疗效果。**
PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review
BACKGROUND: Immunotherapy using PD-1 or PD-L1 inhibitors has been increasingly reported in a variety of non-melanoma skin cancers (NMSCs). OBJECTIVE: To analyze the evidence of PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer. METHODS: A primary literature search was conducted with PubMed, Cochrane Library EMBASE, Web of Science, and CINAHL through October 28, 2018 to include studies on the use of PD-1 or PD-L1 inhibitor in human subjects for non-melanoma skin cancer. Two reviewers independently performed study selection, data extraction and critical appraisal. RESULTS: Fifty-one articles were included in this systematic review. The most robust evidence was in the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinomas, as supported by phase 1 and 2 clinical trials. Treatment of basal cell carcinoma, cutaneous sarcoma, sebaceous carcinoma and malignant peripheral nerve sheath tumor also showed benefit with PD-1/PD-L1 inhibitors but data is limited. There does not appear to be efficacy for PD-1/PD-L1 inhibitors in cutaneous lymphomas. LIMITATIONS: More investigation is needed to determine the efficacy, tumor responsiveness, and the safety profile of PD-1 and PD-L1 inhibitors in NMSC. CONCLUSION: PD-1 and PD-L1 inhibitors exhibit treatment efficacy in a variety of non-melanoma skin cancers.
pmid: 31163235 J Am Acad Dermatol 影响因子: 7.102 发表日期: 20190601 官网 免费下载